Whalesbook
Suno Suno! Q-Line Biotech ka IPO khul raha hai May 21, 2026 ko aur band hoga May 25, 2026 tak. Iska target hai ₹214.48 crore raise karna. Share ka price ₹326 se lekar ₹343 ke beech mein hoga. Is IPO se mile paise mein se ₹110 crore working capital ke liye use honge aur ₹90 crore loan chukane ke kaam aayenge. Stock list hoga NSE SME platform par May 29, 2026 ko. Ye iss saal ka sabse bada SME IPO hai, aur pata hai, abhi SME market mein investors thoda savdhan ho gaye hain regulations change hone ke baad.
Toh company hai kya? Ye Uttar Pradesh se hai aur diagnostic equipment aur In-Vitro Diagnostic (IVD) products bechti hai. Business toh badh raha hai, revenue FY25 mein ₹322.58 crore ho gaya tha, jo FY24 ke ₹206.45 crore se kaafi zyada hai. Lekin, bhai profit ka scene thoda utar-chadaav wala raha. FY25 mein PAT ₹28.13 crore tha, jo FY24 ke ₹34.44 crore se kam hai. Isme ek ₹16.96 crore ka exceptional loss bhi tha. IVD market India mein $394.76 million ka hai aur 4.6% annual growth expected hai. Company apne manufacturing, R&D, aur product range ko strength batati hai, par market mein competition toh hai hi.
Ab aata hai sabse important wala part - woh toh hai risk! April 2026 mein CRISIL Ratings ne company ka rating 'CRISIL B/Stable/CRISIL A4 Issuer Not Cooperating' kar diya. Reason? Information ki kami aur management ka cooperation na karna. Bhai, ye toh seedha warning sign hai governance aur transparency ke liye. Company par ₹242.6 crore ka outstanding loan bhi tha December 2025 tak. IPO se debt kam toh hoga, par abhi bhi external funding pe depend karte hain. Management margins ko 26-28% tak le jaana chahta hai, par margins volatile rahe hain. Aur ek badi baat, inke top 10 customers se hi 82.17% revenue aata hai FY25 mein. Matlab client base concentration kaafi hai.
High price pe dekhein toh stock FY25 earnings per share (₹28.63) ke 11.98 times par trade kar raha hai. Abhi Grey Market Premium (GMP) 12.24% ke aas-paas dikha raha hai listing gain ka, par ye kabhi bhi reliable nahi hota. Overall, iss baar SME IPOs mein investors strong fundamentals aur good governance wali companies ko zyada importance de rahe hain. Q-Line Biotech ko apna expansion plan pura karna hoga aur efficiency badhani hogi, especially woh governance issues jo CRISIL downgrade ne highlight kiye hain.